No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NPCE NeuroPace
- 13.390
- +0.400+3.08%
Close Apr 26 16:00 ET
- 13.110
- -0.280-2.09%
Post 18:21 ET
384.56MMarket Cap-10543P/E (TTM)
13.679High12.940Low69.09KVolume13.050Open12.990Pre Close913.22KTurnover0.59%Turnover RatioLossP/E (Static)28.72MShares18.15052wk High18.62P/B156.93MFloat Cap3.80052wk Low--Dividend TTM11.72MShs Float27.380Historical High--Div YieldTTM5.69%Amplitude1.220Historical Low13.218Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
NeuroPace(NPCE.US) 10% Shareholder Sells US$25,040.86 in Common Stock
$NeuroPace(NPCE.US)$ 10% Shareholder ORBIMED ADVISORS LLC sold 1,781 shares of common stock on Apr 24, 2024 at an average price of $14.06 for a total value of $25,040.86. This transaction involves oth
NeuroPace(NPCE.US) 10% Shareholder Sells US$913.06K in Common Stock
$NeuroPace(NPCE.US)$ 10% Shareholder ORBIMED ADVISORS LLC sold 64,653 shares of common stock on Apr 19, 22, 23, 2024 at an average price of $14.12 for a total value of $913.06K. This transaction invol
NeuroPace(NPCE.US) 10% Shareholder Sells US$238.23K in Common Stock
$NeuroPace(NPCE.US)$ 10% Shareholder ORBIMED ADVISORS LLC sold 16,992 shares of common stock on Apr 16, 17, 18, 2024 at an average price of $14.02 for a total value of $238.23K. This transaction invol
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report
NeuroPace(NPCE.US) 10% Shareholder Sells US$7.03 Million in Common Stock
$NeuroPace(NPCE.US)$ 10% Shareholder ORBIMED ADVISORS LLC sold 485K shares of common stock on Apr 11, 12, 2024 at an average price of $14.49 for a total value of $7.03 million. This transaction involv
Is NeuroPace (NASDAQ:NPCE) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
Comments
Analysts show improved sentiment towards NeuroPace, upgrading their numbers and reducing losses per share. A wide gap in price targets implies a broad range of business scenarios. NeuroPace is expected to outpace industry growth.
Earnings Update: Here's Why Analysts Just Lifted Their NeuroPace, Inc. (NASDAQ:NPCE) Price Target To US$16.00NeuroPace's high P/S ratio is justified by expected strong revenue growth, outpacing the Medical Equipment industry. Shareholders are optimistic about future revenues, holding onto their shares.
ColumnsTop upgrades and downgrades on 4/6
Upgrades
• $Banc of California(BANC.US$: Raymond James Upgrades to Outperform from Market Perform - PT $22
• $Cullen/Frost Bankers(CFR.US$: Raymond James Upgrades to Outperform from Market Perform
• $W.W. Grainger(GWW.US$: Wolfe Research Upgrades to Outperform from Peerperform
• $Invitation Homes Inc(INVH.US$: Evercore ISI Upgrades to Outperform from In Line - PT $46 (from $44)
• $PCB Bancorp(PCB.US$: Raymond James Upgrades to Outperform from Market Perfor...
• $Banc of California(BANC.US$: Raymond James Upgrades to Outperform from Market Perform - PT $22
• $Cullen/Frost Bankers(CFR.US$: Raymond James Upgrades to Outperform from Market Perform
• $W.W. Grainger(GWW.US$: Wolfe Research Upgrades to Outperform from Peerperform
• $Invitation Homes Inc(INVH.US$: Evercore ISI Upgrades to Outperform from In Line - PT $46 (from $44)
• $PCB Bancorp(PCB.US$: Raymond James Upgrades to Outperform from Market Perfor...
7
$NeuroPace(NPCE.US$ So the price action on this really looks like the bull run will take it up.
It recently ipo'd so theres a ton of volume surging through this.
The macd doesnt look to good but it could continue to churn upward.
The vortex5 its about to cross the .75 line and would that be the buy signal?
Will we see institutional buying at these levels?
It recently ipo'd so theres a ton of volume surging through this.
The macd doesnt look to good but it could continue to churn upward.
The vortex5 its about to cross the .75 line and would that be the buy signal?
Will we see institutional buying at these levels?
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg